STOCK TITAN

Fresenius Medical Care AG - $FMS STOCK NEWS

Welcome to our dedicated page for Fresenius Medical Care news (Ticker: $FMS), a resource for investors and traders seeking the latest updates and insights on Fresenius Medical Care stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fresenius Medical Care's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fresenius Medical Care's position in the market.

Rhea-AI Summary
Fresenius Medical Care announces FDA clearance of VersiHD with GuideMe Software
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
partnership
-
Rhea-AI Summary
Fresenius Medical Care, a leading provider of products and services for individuals with renal diseases, reported organic growth in the second quarter. The company achieved visible productivity improvements in Care Delivery and savings from its transformation program. The legal form conversion to a German Stock Corporation was approved by shareholders. Operating income guidance range for FY 2023 was narrowed. Key figures for Q2 2023: Revenue of EUR 4,825 million (+1% YoY), operating income of EUR 357 million (+5% YoY), net income of EUR 140 million (-5% YoY).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
Rhea-AI Summary
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has received approval from its shareholders to convert from a partnership limited by shares to a German stock corporation. The conversion is expected to be completed by the end of 2023 and will result in a more efficient decision-making process and greater flexibility in financial strategy. The role of free float shareholders will also be strengthened. Michael Sen has been elected as the Chair of the new Supervisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
Fresenius Medical Care AG

NYSE:FMS

FMS Rankings

FMS Stock Data

12.24B
198.83M
7.3%
0.19%
Kidney Dialysis Centers
Health Care and Social Assistance
Link
United States of America
Bad Homburg Vor Der Hohe

About FMS

Fresenius Medical Care AG & Co. KGaA is an American German healthcare company which provides kidney dialysis services.